You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 10 Current »

FDA Erlotinib (Tarceva) (attachment)

Overall survival analyses of first-line erlotinib

EGFR Exon 19 Deletion in Non-Small Cell Lung Cancer


No files shared here yet.

  • No labels